Journal of Pharmacy And Bioallied Sciences

REVIEW ARTICLE
Year
: 2021  |  Volume : 13  |  Issue : 4  |  Page : 341--351

Can newer anti-diabetic therapies delay the development of diabetic nephropathy?


Sohail Aziz1, Siti Maisharah Sheikh Ghadzi1, Syed Azhar Syed Sulaiman2, Nur Hafzan Md Hanafiah1, Sabariah Noor Harun1 
1 Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
2 Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia; Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia

Correspondence Address:
Dr. Sabariah Noor Harun
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, 11800 Universiti Sains Malaysia, Penang
Malaysia

Type 2 diabetes mellitus (T2DM) is progressive in nature and leads to hyperglycemia-associated microvascular and macrovascular complications. Diabetic nephropathy (DN) is one of the most prominent microvascular complication induced by T2DM and is characterized by albuminuria and progressive loss of kidney function. Aggressive management of hyperglycemia and hypertension has been found effective in delaying the development and progression of DN. Although the conventional antidiabetic treatment is effective in the earlier management of hyperglycemia, the progressive loss of beta cells ultimately needs the addition of insulin to the therapy. The emergence of newer antidiabetic agents may address the limitations associated with conventional antidiabetic therapies, which not only improve the glycemic status but also effective in improving cardio-renal outcomes. Nevertheless, the exact role of these agents and their role in minimizing diabetes progression to DN still needs elaboration. The present review aimed to highlights the impact of these newer antidiabetic agents in the management of hyperglycemia and their role in delaying the progression of diabetes to DN/management of DN in patients with T2DM.


How to cite this article:
Aziz S, Ghadzi SM, Sulaiman SA, Hanafiah NH, Harun SN. Can newer anti-diabetic therapies delay the development of diabetic nephropathy?.J Pharm Bioall Sci 2021;13:341-351


How to cite this URL:
Aziz S, Ghadzi SM, Sulaiman SA, Hanafiah NH, Harun SN. Can newer anti-diabetic therapies delay the development of diabetic nephropathy?. J Pharm Bioall Sci [serial online] 2021 [cited 2022 Oct 5 ];13:341-351
Available from: https://www.jpbsonline.org/article.asp?issn=0975-7406;year=2021;volume=13;issue=4;spage=341;epage=351;aulast=Aziz;type=0